TWI291555B - Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure - Google Patents

Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure Download PDF

Info

Publication number
TWI291555B
TWI291555B TW092120775A TW92120775A TWI291555B TW I291555 B TWI291555 B TW I291555B TW 092120775 A TW092120775 A TW 092120775A TW 92120775 A TW92120775 A TW 92120775A TW I291555 B TWI291555 B TW I291555B
Authority
TW
Taiwan
Prior art keywords
protein
rup41
receptor
sequence
gpcr
Prior art date
Application number
TW092120775A
Other languages
English (en)
Chinese (zh)
Other versions
TW200410985A (en
Inventor
John W Adams
Daniel T Connolly
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of TW200410985A publication Critical patent/TW200410985A/zh
Application granted granted Critical
Publication of TWI291555B publication Critical patent/TWI291555B/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
TW092120775A 2002-08-01 2003-07-30 Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure TWI291555B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40077402P 2002-08-01 2002-08-01

Publications (2)

Publication Number Publication Date
TW200410985A TW200410985A (en) 2004-07-01
TWI291555B true TWI291555B (en) 2007-12-21

Family

ID=31495875

Family Applications (3)

Application Number Title Priority Date Filing Date
TW092120775A TWI291555B (en) 2002-08-01 2003-07-30 Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
TW096144624A TW200815603A (en) 2002-08-01 2003-07-30 Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
TW096125738A TW200800009A (en) 2002-08-01 2003-07-30 Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW096144624A TW200815603A (en) 2002-08-01 2003-07-30 Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
TW096125738A TW200800009A (en) 2002-08-01 2003-07-30 Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure

Country Status (8)

Country Link
US (2) US7611832B2 (enExample)
EP (1) EP1543025A4 (enExample)
JP (1) JP2005534319A (enExample)
CN (1) CN100473662C (enExample)
AU (1) AU2003259237B2 (enExample)
CA (1) CA2494607A1 (enExample)
TW (3) TWI291555B (enExample)
WO (1) WO2004013285A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013285A2 (en) 2002-08-01 2004-02-12 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
CA2586542A1 (en) * 2004-11-08 2006-05-11 University Of Rochester Transgenic non-human animal models of ischemia-reperfusion injury and uses thereof
WO2015131099A1 (en) * 2014-02-28 2015-09-03 The General Hospital Corporation Diagnosis of multiple myeloma and lymphoma
EP3134433A4 (en) * 2014-04-25 2017-10-04 Libramen Naturals Inc. G-protein coupled receptor 22 transformed cell lines and uses therefor
CN107362365B (zh) * 2017-08-21 2020-01-07 武汉大风生物科技有限公司 Gpr31抑制剂在制药中的应用
CN114642668B (zh) * 2020-12-21 2024-04-05 忻佑康医药科技(南京)有限公司 拉坦前列素的药物新用途
CN119351340B (zh) * 2024-10-31 2025-07-08 中国食品药品检定研究院(国家药品监督管理局医疗器械标准管理中心、中国药品检验总所) 一种测定rhTSH药物生物学活性的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024436A2 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US5994097A (en) 1997-08-28 1999-11-30 Incyte Pharmaceuticals, Inc. Polynucleotide encoding human G-protein coupled receptor
JP2003531637A (ja) * 2000-05-03 2003-10-28 アストラゼネカ アクチボラグ 方 法
AU2001282894A1 (en) 2000-07-19 2002-01-30 Deltagen, Inc. Transgenic mice containing targeted gene disruptions
WO2002061432A2 (en) 2001-02-01 2002-08-08 Lifespan Biosciences, Inc. Gpr22, a g protein-coupled receptor (gpcr) and compositions and methods related thereto
EP1470240A4 (en) 2002-02-01 2006-08-30 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES USING 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419 , 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2
WO2004013285A2 (en) 2002-08-01 2004-02-12 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
AU2006304329A1 (en) 2005-10-14 2007-04-26 Arena Pharmaceuticals, Inc. GPR22 and methods relating thereto

Also Published As

Publication number Publication date
US7611832B2 (en) 2009-11-03
US20050238579A1 (en) 2005-10-27
CN1684975A (zh) 2005-10-19
TW200410985A (en) 2004-07-01
AU2003259237B2 (en) 2011-01-06
TW200815603A (en) 2008-04-01
CA2494607A1 (en) 2004-02-12
US20070224127A1 (en) 2007-09-27
TW200800009A (en) 2008-01-01
WO2004013285A3 (en) 2004-06-10
WO2004013285A2 (en) 2004-02-12
CN100473662C (zh) 2009-04-01
JP2005534319A (ja) 2005-11-17
AU2003259237A1 (en) 2004-02-23
EP1543025A4 (en) 2006-03-15
EP1543025A2 (en) 2005-06-22

Similar Documents

Publication Publication Date Title
US7829298B2 (en) Human G protein-coupled receptors for metabolic-related disorders
ES2354390T3 (es) Procedimientos de uso del receptor gpr119 para identificar compuestos útiles para aumentar la masa ósea en un individuo.
JP5769361B2 (ja) 高血糖症および関連障害の処置のための、ヒトｇタンパク質共役レセプターおよびそのモジュレーター
JP2013082748A (ja) インスリン関連障害の処置のためのｇｐｒ４１およびその調節因子
US6599718B1 (en) Growth hormone secretagogue related receptors and nucleic acids
TW200804812A (en) Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
TWI291555B (en) Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
US20160077113A1 (en) Methods of Identifying Candidate Compounds of the Human G Protein-Coupled Receptor, GPR50, as Modulators of Body Mass or Adiposity
TW200817681A (en) Use of GPR101 receptor in methods to identify modulators of hypothalamic proopiomelanocortin (POMC)-derived biologically active peptide secretion useful in the treatment of POMC-derived biologically active peptide-related disorders
US8017313B2 (en) Human G protein-coupled receptor and modulators thereof for the treatment of cardiovascular disorders
TWI338046B (en) Human g protein-coupled receptor and modulators thereof for the treatment of inflammatory disorders
US20090010909A1 (en) Novel GPCR and methods of use of the same
US20070232519A1 (en) Human G protein-coupled receptor and modulators thereof for the treatment of cardiovascualr disorders
JP2004521612A (ja) ３９残基のヒト結節漏斗状ペプチド

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees